|
1.
|
|
19 p, 1.5 MB |
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
/
Wieduwilt, M.J. (University of Oklahoma) ;
Metheny, L. (University Hospitals Seidman Cancer Center) ;
Zhang, M.J. (Medical College of Wisconsin) ;
Wang, H.L. (Center for International Blood and Marrow Transplant Research) ;
Estrada-Merly, N. (Center for International Blood and Marrow Transplant Research) ;
Marks, D.I. (University Hospitals Bristol National Health Service Trust) ;
Samer Al-Homsi, A. (New York University Langone Health) ;
Muffly, L. (Stanford University) ;
Chao, N. (Duke University Medical Center) ;
Rizzieri, D. (Duke University) ;
Gale, R.P. (Imperial College London) ;
Gadalla, S.M. (National Institutes of Health) ;
Cairo, M. (New York Medical College) ;
Mussetti, Alberto (Institut d'Investigacio Biomedica de Bellvitge) ;
Gore, S. (Yale New Haven Hospital) ;
Bhatt, V.R. (University of Nebraska Medical Center) ;
Patel, S.S. (University of Utah) ;
Michelis, F.V. (Princess Margaret Cancer Centre) ;
Inamoto, Y. (National Cancer Center Hospital) ;
Badawy, S.M. (Northwestern University Feinberg School of Medicine) ;
Copelan, E. (Atrium Health) ;
Palmisiano, N. (Thomas Jefferson University) ;
Kharfan-Dabaja, M.A. (Mayo Clinic) ;
Lazarus, H.M. (Case Western Reserve University) ;
Ganguly, S. (University of Kansas Health System) ;
Bredeson, C. (The Ottawa Hospital Transplant and Cellular Therapy Program) ;
Perez, M.A.D. (Hospital Infantil Universitario Niño Jesus) ;
Cassaday, R. (University of Washington) ;
Savani, B.N. (Vanderbilt University Medical Center) ;
Ballen, K. (Division of Hematology/Oncology. University of Virginia Health System) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Wirk, B. (Penn State Cancer Institute) ;
Bacher, U. (University of Bern) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital Center and Research) ;
Bashey, A. (Northside Hospital) ;
Murthy, H.S. (Mayo Clinic) ;
Yared, J.A. (University of Maryland) ;
Aldoss, I. (City of Hope Medical Center) ;
Farhadfar, N. (University of Florida College of Medicine) ;
Liu, H. (University of Chicago Medicine) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Waller, E.K. (Emory University) ;
Solh, M. (Northside Hospital) ;
Seftel, M.D. (University of British Columbia) ;
van der Poel, M. (Maastricht University Medical Center) ;
Grunwald, M.R. (Atrium Health) ;
Liesveld, J.L. (University of Rochester Medical Center) ;
Kamble, R.T. (Baylor College of Medicine) ;
McGuirk, J. (University of Kansas Health System) ;
Munker, R. (University of Kentucky) ;
Cahn, Jean-Yves (Universite Grenoble Alpes) ;
Lee, J.W. (The Catholic University of Korea) ;
Freytes, C.O. (University of Texas Health Science Center) ;
Krem, M.M. (University of Kentucky) ;
Winestone, L.E. (University of California) ;
Gergis, U. (Thomas Jefferson University) ;
Nathan, S. (Rush University Medical Center) ;
Olsson, R.F. (Karolinska Institutet) ;
Verdonck, L.F. (Isala Clinic) ;
Sharma, A. (St. Jude Children's Research Hospital) ;
Ringden, O. (Karolinska Institutet) ;
Friend, B.D. (Baylor College of Medicine) ;
Cerny, J. (University of Massachusetts Medical Center) ;
Choe, H. (The Ohio State University Wexner Medical Center) ;
Chhabra, S. (Center for International Blood and Marrow Transplant Research) ;
Nishihori, T. (Moffitt Cancer Center) ;
Seo, S. (Dokkyo Medical University) ;
George, B. (Christian Medical College) ;
Baxter-Lowe, L.A. (Children's Hospital Los Angeles) ;
Hildebrandt, G.C. (University of Kentucky) ;
de Lima, M. (University Hospitals Case Medical Center) ;
Litzow, M. (Mayo Clinic Rochester) ;
Kebriaei, P. (The University of Texas MD Anderson Cancer Center) ;
Hourigan, C.S. (National Institutes of Health) ;
Abid, M.B. (Medical College of Wisconsin) ;
Weisdorf, D.J. (University of Minnesota) ;
Saber, W. (Center for International Blood and Marrow Transplant Research) ;
Universitat Autònoma de Barcelona
The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. [...]
2022 -  10.1182/bloodadvances.2021004916
Blood advances, Vol. 6 Núm. 1 (november 2022) , p. 339-357
|
|
|
2.
|
|
10 p, 685.7 KB |
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia : the phase 2 CAPTIVATE study
/
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company) ;
Tam, Constantine S. (Monash University) ;
Grigg, Andrew (Austin Hospital) ;
Scarfò, Lydia (Università Vita Salute San Raffaele) ;
Kipps, Thomas J. (University of California. Moores Cancer Center) ;
Srinivasan, Srimathi (Janssen Research & Development) ;
Mali, Raghuveer Singh (Pharmacyclics LLC. an AbbVie Company) ;
Zhou, Cathy (Pharmacyclics LLC. an AbbVie Company) ;
Dean, James P. (Pharmacyclics LLC. an AbbVie Company) ;
Szafer Glusman, Edith (Pharmacyclics LLC. an AbbVie Company) ;
Choi, Michael (University of California)
We evaluated immune cell subsets in patients with chronic lymphocytic leukemia (CLL) who received first-line therapy with 3 cycles of ibrutinib then 13 cycles of ibrutinib plus venetoclax in the minimal residual disease (MRD) cohort of the CAPTIVATE study (NCT02910583). [...]
2023 - 10.1182/bloodadvances.2023010236
Blood advances, Vol. 7 Núm. 18 (26 2023) , p. 5294-5309
|
|
|
3.
|
|
10 p, 345.6 KB |
Momelotinib long-term safety and survival in myelofibrosis : integrated analysis of phase 3 randomized controlled trials
/
Verstovsek, Srdan (The University of Texas, USA) ;
Mesa, Ruben (UT Health San Antonio Cancer Center, San Antonio, USA) ;
Gupta, Vikas (Princess Margaret Cancer Centre, Toronto, Canada) ;
Lavie, David (Hadassah-Hebrew University Medical Center, Jerusalem, Israel) ;
Dubruille, Viviane (Centre Hospitalier Universitaire de Nantes (CHU de Nantes), Nantes, France) ;
Cambier, Nathalie (Centre hospitalier r ' egional universitaire de Lille (CHRU Lille), Lille, France) ;
Platzbecker, Uwe (University of Leipzig, Germany) ;
Hus, Marek (Uniwersytet Medyczny w Lublinie, Lublin, Poland) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Oh, Stephen T. (Washington University School of Medicine, St. Louis, USA) ;
Kiladjian, Jean Jacques (Universite de Paris, France) ;
Vannucchi, Alessandro M. (University of Florence, Careggi University Hospital, Florence, Italy) ;
Gerds, Aaron (Cleveland Clinic, USA) ;
Egyed, Miklos (Teaching Hospital Mor Kaposi, Kaposv ' ar, Hungary) ;
Mayer, Jiří (Masaryk University, Brno, Czech Republic) ;
Sacha, Tomasz (Uniwersytet Jagiellonski Collegium Medicum, Krakow, Poland) ;
Kawashima, Jun (Sierra Oncology, San Mateo, CA) ;
Morris, Marc (Sierra Oncology, San Mateo, CA) ;
Huang, Mei (Sierra Oncology, San Mateo, CA) ;
Harrison, Claire (National Health Services (NHS) Foundation Trust, London, United Kingdom)
Momelotinib is the first inhibitor of Janus kinase 1 (JAK1) and JAK2 shown to also inhibit activin A receptor type 1 (ACVR1), a key regulator of iron homeostasis, and has demonstrated improvements in splenomegaly, constitutional symptoms, and anemia in myelofibrosis (MF). [...]
2023 - 10.1182/bloodadvances.2022009311
Blood advances, Vol. 7 Núm. 14 (july 2023) , p. 3582-3591
|
|
|
4.
|
|
14 p, 2.7 MB |
GPRC5C drives branched-chain amino acid metabolism in leukemogenesis
/
Zhang, Yu Wei (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mess, Julian (University of Freiburg) ;
Lalioti, Maria Eleni (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Romero-Mulero, Mari Carmen (University of Freiburg, Germany) ;
Obier, Nadine (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Karantzelis, Nikolaos (University Medical Center Freiburg, Germany) ;
Rettkowski, Jasmin (University of Freiburg, Germany) ;
Schönberger, Katharina (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Karabacz, Noemie (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Jäcklein, Karin (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) ;
Morishima, Tatsuya (Kumamoto University, Japan) ;
Trincado Alonso, Juan Luis, 1987- (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Romecin, Paola (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martinez, Alba (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Takizawa, Hitoshi (Kumamoto University, Japan) ;
Shoumariyeh, Khalid (University of Freiburg, Germany) ;
Renders, Simon (Heidelberg University Hospital (Alemanya)) ;
Zeiser, Robert (University of Freiburg, Germany) ;
Pahl, Heike L. (University Medical Center Freiburg, Germany) ;
Béliveau, François (Quebec leukemia cell bank. Hopital Maisonneuve-Rosemont, Montreal, Canada) ;
Hébert, Josee (Quebec leukemia cell bank. Hopital Maisonneuve-Rosemont, Montreal, Canada) ;
Lehnertz, Bernhard (University of Montreal, Canada) ;
Sauvageau, Guy (University of Montreal, Canada) ;
Menendez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cabezas-Wallscheid, Nina (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany)
Leukemia stem cells (LSCs) share numerous features with healthy hematopoietic stem cells (HSCs). G-protein coupled receptor family C group 5 member C (GPRC5C) is a regulator of HSC dormancy. However, GPRC5C functionality in acute myeloid leukemia (AML) is yet to be determined. [...]
2023 - 10.1182/bloodadvances.2023010460
Blood advances, Vol. 7 Núm. 24 (december 2023) , p. 7525-7538
|
|
|
5.
|
|
15 p, 3.6 MB |
Unraveling the genetics of transformed splenic marginal zone lymphoma
/
Grau, Marta (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
López, Cristina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Navarro, Alba (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Frigola, Gerard (Hospital Clínic i Provincial de Barcelona) ;
Nadeu, Ferran (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Clot, Guillem (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Bastidas-Mora, Gabriela (Hospital Clínic i Provincial de Barcelona) ;
Alcoceba, Miguel (Hospital Universitario de Salamanca) ;
Baptista, Maria Joao (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Blanes, Margarita (Hospital General Universitario de Elda) ;
Colomer, Dolors (Hospital Clínic i Provincial de Barcelona) ;
Costa, Dolors (Hospital Clínic i Provincial de Barcelona) ;
Domingo-Domenech, Eva (Institut d'Investigació Biomèdica de Bellvitge) ;
Enjuanes, Anna (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Escoda, Lourdes (Hospital Universitari Joan XXIII de Tarragona) ;
Forcada, Pilar (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Giné, Eva (Hospital Clínic i Provincial de Barcelona) ;
Lopez-Guerra, Mónica (Hospital Clínic i Provincial de Barcelona) ;
Ramón, Olga (Hospital General de Igualada) ;
Rivas-Delgado, Alfredo (Hospital Clínic i Provincial de Barcelona) ;
Folch, Laura Vicente (Consorci Sanitari de Terrassa) ;
Wotherspoon, Andrew (Royal Marsden NHS Foundation Trust, United Kingdom) ;
Climent, Fina (Institut d'Investigació Biomèdica de Bellvitge) ;
Campo, Elias (Hospital Clínic i Provincial de Barcelona) ;
López-Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ;
Matutes, Estella (Hospital Clínic i Provincial de Barcelona) ;
Bea, Sílvia (Hospital Clínic i Provincial de Barcelona)
The genetic mechanisms associated with splenic marginal zone lymphoma (SMZL) transformation are not well defined. We studied 41 patients with SMZL that eventually underwent large B-cell lymphoma transformation. [...]
2023 - 10.1182/bloodadvances.2022009415
Blood advances, Vol. 7 Núm. 14 (july 2023) , p. 3695-3709
|
|
|
6.
|
|
14 p, 3.0 MB |
The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia
/
Sun, Clare (Hematology Branch. National Heart. Lung. and Blood Institute. National Institutes of Health, Bethesda) ;
Chen, Yun Ching (Bioinformatics and Computational Biology Core. National Heart. Lung. and Blood Institute. National Institutes of Health, Bethesda) ;
Zurita, Aina Martinez (Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA) ;
Baptista, Maria Joao (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Pittaluga, Stefania (Laboratory of Pathology. National Cancer Institute. National Institutes of Health, Bethesda) ;
Liu, Delong (Bioinformatics and Computational Biology Core. National Heart. Lung. and Blood Institute. National Institutes of Health, Bethesda) ;
Rosebrock, Daniel (Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge MA) ;
Gohil, Satyen Harish (University College London) ;
Saba, Nakhle S. (Tulane University, New Orleans, LA) ;
Davies-Hill, Theresa (Laboratory of Pathology. National Cancer Institute. National Institutes of Health, Bethesda) ;
Herman, Sarah E.M. (Hematology Branch. National Heart. Lung. and Blood Institute. National Institutes of Health, Bethesda) ;
Getz, Gad (Harvard Medical School, Boston, MA) ;
Pirooznia, Mehdi (Bioinformatics and Computational Biology Core. National Heart. Lung. and Blood Institute. National Institutes of Health, Bethesda) ;
Wu, Catherine J. (Department of Medicine. Brigham and Women's Hospital, Boston, MA) ;
Wiestner, Adrian (Hematology Branch. National Heart. Lung. and Blood Institute. National Institutes of Health, Bethesda)
In chronic lymphocytic leukemia (CLL), B-cell receptor signaling, tumor-microenvironment interactions, and somatic mutations drive disease progression. To better understand the intersection between the microenvironment and molecular events in CLL pathogenesis, we integrated bulk transcriptome profiling of paired peripheral blood (PB) and lymph node (LN) samples from 34 patients. [...]
2023 - 10.1182/bloodadvances.2021006941
Blood advances, Vol. 7 Núm. 1 (january 2023) , p. 145-158
|
|
|
7.
|
|
20 p, 1.9 MB |
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
/
Menghrajani, Kamal (Leukemia Service) ;
Gomez-Arteaga, Alexandra (Memorial Sloan Kettering Cancer Center) ;
Madero-Marroquin, Rafael (Icahn School of Medicine. Mount Sinai St Luke's and Mount Sinai West) ;
Zhang, Mei-Jie (Medical College of Wisconsin) ;
Bo-Subait, Khalid (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine) ;
Sanchez, Jonathan (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine) ;
Wang, Hai-Lin (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital Center and Research) ;
Assal, Amer (Columbia University Irving Medical Center) ;
Bacher, Vera Ulrike (Bern University Hospital) ;
Badawy, Sherif M. (Northwestern University Feinberg School of Medicine) ;
Bejanyan, Nelli (Department of Blood and Marrow Transplant and Cellular Immunotherapy. Moffitt Cancer Center) ;
Bhatt, Vijaya Raj (University of Nebraska Medical Center) ;
Bredeson, Christopher (Ottawa Hospital Research Institute) ;
Byrne, Michael (Vanderbilt University Medical Center) ;
Castillo, Paul (UF Health Shands Children's Hospital) ;
Cerny, Jan (University of Massachusetts Medical Center) ;
Chhabra, Saurabh (Medical College of Wisconsin) ;
Ciurea, Stefan Octavian (The University of Texas MD Anderson Cancer Center) ;
DeFilipp, Zachariah (Massachusetts General Hospital) ;
Farhadfar, Nosha (Division of Hematology/Oncology. University of Florida College of Medicine) ;
Gadalla, Shahinaz (Division of Cancer Epidemiology and Genetics. National Cancer Institute (NCI) Clinical Genetics Branch. National Institutes of Health (NIH)) ;
Gale, Robert Peter (Imperial College London) ;
Ganguly, Siddhartha (Division of Hematological Malignancy and Cellular Therapeutics. University of Kansas Health System) ;
Gowda, Lohith (Section of Hematology. Department of Medicine. Yale University School of Medicine. Yale Comprehensive Cancer Center. Yale New Haven Hospital) ;
Grunwald, Michael R. (Department of Hematologic Oncology and Blood Disorders. Levine Cancer Institute. Atrium Health) ;
Hashmi, Shahrukh (Oncology Center. King Faisal Specialist Hospital and Research Center) ;
Hildebrandt, Gerhard (Markey Cancer Center. University of Kentucky) ;
Kanakry, Christopher G. (Experimental Transplantation and Immunology Branch. Center for Cancer Research. NCI. NIH) ;
Kansagra, Ankit (UT Southwestern Medical Center. Blood and Marrow Transplant Program) ;
Khimani, Farhad (H Lee Moffitt Cancer Center and Research Institute) ;
Krem, Maxwell (Markey Cancer Center. University of Kentucky College of Medicine) ;
Lazarus, Hillard (Department of Medicine. University Hospitals Case Medical Center. Seidman Cancer Center. Case Comprehensive Cancer Center. Case Western Reserve University) ;
Liu, Hongtao (Section of Hematology/Oncology. University of Chicago Medicine) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Michelis, Fotios V. (Allogeneic Blood and Marrow Transplant Program. Princess Margaret Cancer Centre) ;
Nathan, Sunita (Section of Bone Marrow Transplant and Cell Therapy. Rush University Medical Center) ;
Nishihori, Taiga (The Fred and Pamela Buffett Cancer Center. University of Nebraska Medical Center) ;
Olsson, Richard (Centre for Clinical Research Sormland. Uppsala University) ;
Reshef, Ran (Columbia Center for Translational Immunology. Columbia University Medical Center) ;
Rizzieri, David (Division of Hematologic Malignancies and Cellular Therapy. Duke University) ;
Rowe, Jacob M. (Department of Hematology. Shaare Zedek Medical Center) ;
Savani, Bipin N. (Division of Hematology/Oncology. Department of Medicine. Vanderbilt University Medical Center) ;
Seo, Sachiko (Dokkyo Medical University) ;
Sharma, Akshay (St. Jude Children's Research Hospital (Memphis, Estats Units d'Amèrica)) ;
Solh, Melhem (The Blood and Marrow Transplant Group of Georgia. Northside Hospital) ;
Ustun, Celalettin (Hematology. Oncology. and Cell Therapy. Rush University Medical Center) ;
Verdonck, Leo F. (Department of Hematology and Oncology. Isala Clinic) ;
Hourigan, Christopher (National Heart Lung. and Blood Institute. NIH) ;
Sandmaier, Brenda (Clinical Research Division. Fred Hutchinson Cancer Research Center) ;
Litzow, Mark (Division of Hematology and Transplant Center. Mayo Clinic Rochester) ;
Kebriaei, Partow (Department of Stem Cell Transplantation. Division of Cancer Medicine. The University of Texas MD Anderson Cancer Center) ;
Weisdorf, Daniel (Division of Hematology. Oncology and Transplantation. Department of Medicine. University of Minnesota) ;
Zhang, Yanming (Department of Pathology. Memorial Sloan Kettering Cancer Center) ;
Tallman, Martin S. (Department of Pathology. Memorial Sloan Kettering Cancer Center) ;
Saber, Wael (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine)
Little is known about whether risk classification at diagnosis predicts post-hematopoietic cell transplantation (HCT) outcomes in patients with acute myeloid leukemia (AML). We evaluated 8709 patients with AML from the CIBMTR database, and after selection and manual curation of the cytogenetics data, 3779 patients in first complete remission were included in the final analysis: 2384 with intermediate-risk, 969 with adverse-risk, and 426 with KMT2A-rearranged disease. [...]
2022 - 10.1182/bloodadvances.2021004881
Blood advances, Vol. 6 Núm. 3 (august 2022) , p. 828-847
|
|
|
8.
|
|
9 p, 381.0 KB |
Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura
/
Pascual, Cristina (Instituto de Investigación Sanitaria Gregorio Marañón. Servicio de Hematología) ;
Mingot-Castellano, María Eva (Instituto de Biomedicina de Sevilla) ;
Kerguelen Fuentes, Ana E. (Hospital Universitario La Paz (Madrid)) ;
García-Arroba, José (Hospital Universitari Joan XXIII. Banc de Sang i Teixits) ;
Cid, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Jimenez, Moraima (Vall d'Hebron Institut d'Oncologia) ;
Valcárcel, David (Vall d'Hebron Institut d'Oncologia) ;
Gómez-Seguí, Inés (Hospital La Fe. Servicio de Hematología) ;
de la Rubia, Javier (Hospital La Fe. Servicio de Hematología) ;
Martin, Paz (Hospital Clínico San Carlos. Unidad de Aféresis Terapéutica. Servicio de Hematología) ;
Goterris, Rosa (Hospital Clínico Universitario de Valencia. Servicio de Hematología. INCLIVA Instituto de Investigación Sanitaria) ;
Hernández, Luis (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Tallón, Inmaculada (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Varea, Sara (Hospital San Chinarro) ;
Fernández, Marta (Complejo Hospitalario Universitario de A Coruña) ;
García-Muñoz, Nadia (Hospital Universitari de Bellvitge) ;
Vara, Míriam (Hospital Universitario de Cruces. Servicio de Hematología) ;
Fernández-Zarzoso, Miguel (Hospital Universitari Doctor Peset (València)) ;
García-Candel, Faustino (Hospital Clínico Universitario Virgen de la Arrixaca (El Palmar, Múrcia)) ;
Paciello, María Liz (Hospital 12 de Octubre (Madrid)) ;
García-García, Irene (Hospital 12 de Octubre (Madrid)) ;
Zalba, Saioa (Hospital Universitario de Navarra) ;
Campuzano, Verónica (Hospital Universitario de Burgos) ;
Gala, José María (Hospital Universitario Central de Asturias) ;
Vidan, Julia (Complejo Asistencial Universitario de León. Unidad de Aféresis y Transfusión. Servicio de Hematología y Hemoterapia) ;
Moreno-Jiménez, Gemma (Hospital Ramón y Cajal. Servicio de Hematología) ;
López Lorenzo, José Luis (Hospital Universitario Fundación Jiménez Díaz. Servicio de Hematología) ;
González Arias, Elena (Hospital Universitario General de Villalba) ;
Freiría, Carmen (Consorci Hospitalari Provincial de Castelló) ;
Solé, María (Hospital General Juan Ramón Jiménez) ;
Ávila Idrovo, Laura Francisca (Hospital Universitario de Canarias (La Laguna)) ;
Hernández Castellet, José Carlos (Hospital Universitario Puerta del Mar (Cadis, Andalusia)) ;
Cruz, Naylen (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Lavilla, Esperanza (Hospital Universitario Lucus Augusti (Lugo)) ;
Pérez-Montaña, Albert (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Atucha, Jon Ander (Hospital de Basurto (Bilbao, Biscaia)) ;
Moreno Beltrán, María Esperanza (Hospital Costa del Sol (Marbella)) ;
Moreno Macías, Juan Ramón (Complejo Hospitalario Universitario de Albacete) ;
Salinas, Ramón (Universitat Internacional de Catalunya) ;
del Rio-Garma, Julio (Complejo Hospitalario Universitario de Ourense. Servicio de Hematología)
Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. [...]
2022 - 10.1182/bloodadvances.2022008028
Blood advances, Vol. 6 Núm. 24 (December 2022) , p. 6219-6227
|
|
|
9.
|
|
11 p, 340.8 KB |
Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe
/
Rafii, Hanadi (Centre Scientifique de Monaco) ;
Ruggeri, Annalisa (IRCCS San Raffaele Scientific Institute (Milan, Itàlia)) ;
Kenzey, Chantal (Centre Scientifique de Monaco) ;
Sanz, Jaime (Hospital Universitari i Politècnic La Fe (València)) ;
Peffault De La Tour, Régis (Assistance Publique-Hôpitaux de Paris) ;
Esquirol, Albert (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Michel, Gérard (Hopital pédiatrique de la Timone (Marseille, França)) ;
Chevallier, Patrice (Hospital Hotel Dieu (Nantes, França)) ;
Rubio, Marie-Thérèse (CHRU Nancy (Nancy, França)) ;
Cornelissen, Jan J. (Erasmus MC-Daniel den Hoed Cancer Centre) ;
Michallet, Mauricette (Centre Leon Berard) ;
Volt, Fernanda (Monacord, Centre Scientifique de Monaco) ;
Rivera-Franco, Monica M. (Centre Scientifique de Monaco) ;
Scigliuolo, Graziana Maria (Centre Scientifique de Monaco) ;
Cappelli, Barbara (Centre Scientifique de Monaco) ;
Rocha, Vanderson (São Paulo Medical School) ;
Gluckman, Eliane (Centre Scientifique de Monaco) ;
Universitat Autònoma de Barcelona
Subsequent neoplasms (SNs) compromise long-term survivors after hematopoietic cell transplantation. We performed a retrospective analysis of SNs in 10 358 recipients of umbilical cord blood transplantation (UCBT) from 1988 to 2018. [...]
2022 - 10.1182/bloodadvances.2022007941
Blood advances, Vol. 7 (november 2022) , p. 1976-1986
|
|
|
10.
|
|
11 p, 1.4 MB |
Up to 8-year follow-up from RESONATE-2 : first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
/
Barr, Paul M. (Clinical Trials Office. Wilmot Cancer Institute. University of Rochester Medical Center) ;
Owen, Carolyn (Division of Hematology & Hematological Malignancies. Tom Baker Cancer Centre. University of Calgary) ;
Robak, Tadeusz (Medical University of Lodz) ;
Tedeschi, Alessandra (Department of Hematology. Azienda Socio Sanitaria Territoriali Grande Ospedale Metropolitano Niguarda) ;
Bairey, Osnat (Department of Hematology. Rabin Medical Center) ;
Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center) ;
Hillmen, Peter (Department of Haematology. The Leeds Teaching Hospitals. St. James Institute of Oncology) ;
Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Cente) ;
Dearden, Claire (Haemato-Oncology Department. The Royal Marsden Hospital) ;
Grosicki, Sebastian (Department of Hematology and Cancer Prevention. School of Public Health. Silesian Medical University) ;
McCarthy, Helen (Royal Bournemouth General Hospital. Haematology Department) ;
Li, Jian-Yong (Jiangsu Province Hospital. Department of Hematology) ;
Offner, Fritz (Universitair Ziekenhuis Gent. Department of Clinical Hematology) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Zhou, Ccathy (Biostatistics. Pharmacyclics LLC. An AbbVie Company) ;
Hsu, Emily (Clinical Sciences. Pharmacyclics LLC. An AbbVie Company) ;
Szoke, Anita (Clinical Sciences. Pharmacyclics LLC. An AbbVie Company) ;
Kipps, Thomas J. (University of California San Diego. Department of Medicine. Moores Cancer Center) ;
Ghia, Paolo (Università Vita-Salute San Raffaele. Department of Onco-Hematology. Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele) ;
Universitat Autònoma de Barcelona
2022 - 10.1182/bloodadvances.2021006434
Blood advances, Vol. 6 Núm. 11 (june 2022) , p. 3440-3450
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
